Group 1 - The core viewpoint of the article is that Citigroup has initiated coverage on MicroPort Medical (00853) with a "Buy" rating and a target price of HKD 16, reflecting a price-to-earnings ratio of 39 times for 2026 and 24 times for 2027, positioning it as one of the industry favorites [1] - MicroPort Medical's net loss for the first half of 2025 has narrowed by 66% year-on-year, and Citigroup expects the company to achieve profitability in the second half of 2025 [1] - Citigroup anticipates that the high-growth overseas platform will achieve a year-on-year growth of 70% to 80% in 2025, with this growth trend likely to continue into 2026 [1] Group 2 - Citigroup maintains its revenue forecasts for MicroPort Medical for the fiscal years 2025, 2026, and 2027 at RMB 1.098 billion, RMB 1.253 billion, and RMB 1.422 billion respectively [1] - The earnings forecast for the fiscal year 2025 has been revised upward by 17% to a loss of RMB 41 million, while the earnings estimates for 2026 and 2027 remain at RMB 95 million and RMB 154 million respectively [1]
花旗：重新覆盖微创医疗(00853)予“买入”评级 目标价16港元